ULTRAGENYX PHARMACEUTICAL INC. (RARE) Deferred Tax Assets, in Process Research and Development

ULTRAGENYX PHARMACEUTICAL INC. Deferred Tax Assets, in Process Research and Development

ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Deferred Tax Assets, in Process Research and Development of $34.00 million as of 2025-12-31, per its 10-K filed 2026-02-18.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross

us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-02-18

• 2025-12-31: Deferred Tax Assets, in Process Research and Development $34.00M.
• 2024-12-31: Deferred Tax Assets, in Process Research and Development $212.00M; Deferred Tax Assets, in Process Research and Development as first filed $211.97M.
• 2023-12-31: Deferred Tax Assets, in Process Research and Development $149.90M.
• 2022-12-31: Deferred Tax Assets, in Process Research and Development $75.33M.